FDA Approves 1st Non-Opioid Pain Drug in 20 Years
On January 16, 2025, the Food and Drug Administration (FDA) issued an order banning FD&C Red No.3 in food and ingested drugs.1 Food and ingested
There is no evidence that a senior Food and Drug Administration (FDA) worker was arrested after samples of the H5N1 bird flu virus were found in his fridge. The narrative stems from a website whose false stories about high-profile arrests Reuters has fact-checked in the past.
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to severe acute pain in adults.
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Vertex Pharmaceuticals Inc. gained US approval for the first new type of painkiller in more than two decades, paving the way for a safer alternative to addictive opioids that have been linked to hundreds of thousands of deaths.
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.
A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous
The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be eligible for treatment with an antibody drug conjugate known as Enhertu.